PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
Ptc Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Market Cap | $5.14B | $197.05M |
| Enterprise Value | $3.50B | $106.56M |
| PS Ratio | 5.09 | 3.93 |
Enterprise value
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 3.47 | 2.69 |
| EV / EBITDA | 19.33 | 14.86 |
| EV / EBIT | 27.84 | 19.00 |
Income (trailing twelve months)
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.01B | $57.94M |
| Operating Income | $125.60M | -$21.44M |
| Pretax Income | -$67.07M | -$14.45M |
| Net Income | -$38.38M | -$22.46M |
| EBITDA | $180.90M | -$16.91M |
| EPS (Diluted) | -$0.37 | -$0.83 |
Margins
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Operating Margin | 12.5% | -44.5% |
| Pretax Margin | -6.65% | -13.0% |
| Profit Margin | -3.80% | -39.2% |
| EBITDA Margin | 17.9% | -31.3% |
| FCF Margin | -3.94% | -8.85% |
Returns
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -1.30% | -41.0% |
| Return on Capital Employed (ROCE) | 5.07% | -37.8% |
Growth
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -42.8% | 6.01% |
| Net Income Growth (YoY) | -106.1% | -37.7% |
| EPS Growth (YoY) | -105.3% | -29.2% |
| FCF Growth (YoY) | -105.7% | 2.34% |
| Revenue Growth (3Y CAGR) | 35.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 35.4% | 6.42% |
Balance sheet
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.23B | $62.42M |
| Total Debt | $590.97M | $120.13M |
| Net Cash (Debt) | $1.64B | $15.68M |
| Net Cash Per Share | $19.63 | $0.65 |
| Equity (Book Value) | -$165.36M | $48.79M |
| Book Value Per Share | -$1.98 | $1.36 |
| Tangible Book Value | -$650.63M | $23.06M |
| Working Capital | $1.85B | $75.77M |
Financial position
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.39 | 3.30 |
| Quick Ratio | 3.20 | 2.39 |
| Debt / EBITDA | 3.27 | 3.35 |
| Net Debt / EBITDA | -9.06 | 2.22 |
Cash flow (trailing twelve months)
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$30.50M | -$12.35M |
| Capital Expenditures | -$9.28M | -$1.06M |
| Free Cash Flow | -$39.78M | -$20.28M |
| FCF Per Share | -$0.48 | -$0.41 |
Efficiency
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.38 |
| Revenue Per Employee | $1.02M | $398.96K |
| Profits Per Employee | -$38.73K | -$732.08K |
| Employee Count | 991 | 73 |
Dividends and yields
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -0.75% | -21.2% |
| FCF Yield | -0.77% | -7.64% |
Shares
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 83,460,800 | 59,128,900 |
| Shares Change (YoY) | 11.1% | 11.1% |
| Shares Change (QoQ) | 0.54% | 0.54% |
| Float | 80,916,200 | 48,744,500 |
| Shares Held by Insiders | 3.05% | 11.8% |
| Shares Held by Institutions | 120.2% | 59.4% |
Taxes
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$28.69M | $91.50K |
Scores
| Measure | Ptc Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 0.78 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Ptc Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.